Literature DB >> 10229803

Annexin V delays apoptosis while exerting an external constraint preventing the release of CD4+ and PrPc+ membrane particles in a human T lymphocyte model.

C Gidon-Jeangirard1, B Hugel, V Holl, F Toti, J L Laplanche, D Meyer, J M Freyssinet.   

Abstract

Phosphatidylserine exposure in the exoplasmic leaflet of the plasma membrane is one of the early hallmarks of cells undergoing apoptosis. The shedding of membrane particles carrying Ags testifying to their tissue origin is another characteristic feature. Annexin V, a protein of as yet unknown specific physiologic function, presents a high Ca2+-dependent affinity for phosphatidylserine and forms two-dimensional arrays at the membrane surface. In this study, we report the delaying action of annexin V on apoptosis in the CEM human T cell line expressing CD4 and the normal cellular prion protein (PrPc), two Ags of particular relevance to cell degeneration and with different attachments to the membrane. The effect of annexin V was additive to that of z-Val-Ala-Asp-fluoromethyl ketone, a potent caspase inhibitor. Annexin V significantly reduced the degree of proteolytic activation of caspase-3, and totally blocked the release of CD4+ and PrPc+ membrane particles. z-Val-Ala-Asp-fluoromethyl ketone was a more powerful antagonist of caspase-3 processing, but prevented the shedding of CD4+ vesicles only partially and had no effect on that of PrPc+ ones. These results suggest that an external membrane constraint, such as that exerted by annexin V, has important consequences on the course of programmed cell death and on the dissemination of particular Ags. In vivo, annexin V had a significant protective effect against spleen weight loss in mice treated by an alkylating agent previously shown to induce lymphocyte apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229803

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Quantitative proteomic analysis of exosomes from HIV-1-infected lymphocytic cells.

Authors:  Ming Li; Jason M Aliotta; John M Asara; Lynne Tucker; Peter Quesenberry; Michelle Lally; Bharat Ramratnam
Journal:  Proteomics       Date:  2012-07       Impact factor: 3.984

2.  Protective effect of the apoptosis-sensing nanoparticle AnxCLIO-Cy5.5.

Authors:  Howard H Chen; Yan Feng; Ming Zhang; Wei Chao; Lee Josephson; Stanley Y Shaw; David E Sosnovik
Journal:  Nanomedicine       Date:  2011-06-24       Impact factor: 5.307

3.  Novel piperazine induces apoptosis in U937 cells.

Authors:  Josiah J Sampson; Isaac O Donkor; Tien L Huang; Samuel E Adunyah
Journal:  Int J Biochem Mol Biol       Date:  2011-01-30

4.  Potent cardioprotection from ischemia-reperfusion injury by a two-domain fusion protein comprising annexin V and Kunitz protease inhibitor.

Authors:  C-H Yeh; T-P Chen; Y-C Wang; S-W Fang; T-C Wun
Journal:  J Thromb Haemost       Date:  2013-08       Impact factor: 5.824

Review 5.  Apoptosis in the vasculature: mechanisms and functional importance.

Authors:  Z Mallat; A Tedgui
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

6.  Delphinidin, an active compound of red wine, inhibits endothelial cell apoptosis via nitric oxide pathway and regulation of calcium homeostasis.

Authors:  Sophie Martin; Grégory Giannone; Ramaroson Andriantsitohaina; M Carmen Martinez
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

7.  Anti-annexin V antibodies in Takayasu's arteritis: prevalence and relationship with disease activity.

Authors:  N K Tripathy; N Sinha; S Nityanand
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

Review 8.  The role of the cellular prion protein in the immune system.

Authors:  J D Isaacs; G S Jackson; D M Altmann
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

9.  Recent developments in the pathogenesis, diagnosis, and therapy of prion diseases.

Authors:  A Aguzzi
Journal:  Dialogues Clin Neurosci       Date:  2001-03       Impact factor: 5.986

10.  99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies.

Authors:  Frédéric L W V J Schaper; Chris P Reutelingsperger
Journal:  Cancers (Basel)       Date:  2013-05-15       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.